Trial Status:
Closed
A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Purpose:
A study with Combination Therapy Ivacaftor and Lumacaftor in Children 6-11 for Cystic Fibrosis homozygote genotype DeltaF508.
Sponsor:
Vertex Pharmaceuticals
Principal Investigator:
Cori Daines, MD
Contact Information:
Osmara Y. Molina de Rodriguez, MS
Cell: (520) 891-6767 or Office: (520) 626-3910
Link to Study:
Principal Investigator:
Research Area:
Clinical and Population Research